PharmAla Biotech is a Canadian biotechnology company specializing in the research, development, and manufacturing of clinical-grade MDMA and novel MDXX compounds. PharmAla operates two primary businesses: the manufacturing of MDMA for the treatment of PTSD, and the research and development of novel MDMA Analogs (MDXX drugs) for the treatment of a diverse array of psychiatric and central nervous system disorders. PharmAla is the global leader in MDMA manufacturing, with clients like the US Veterans Affairs Administration, the US Military, and a broad array of university clients (Yale, Johns Hopkins, Harvard, UCLA, and many others). PharmAla is publicly traded, and was the fastest-growing public stock in Canada in 2023.